WO2007123961A3 - Purification processes for isolating purified vesicular stomatitis virus from cell culture - Google Patents

Purification processes for isolating purified vesicular stomatitis virus from cell culture Download PDF

Info

Publication number
WO2007123961A3
WO2007123961A3 PCT/US2007/009510 US2007009510W WO2007123961A3 WO 2007123961 A3 WO2007123961 A3 WO 2007123961A3 US 2007009510 W US2007009510 W US 2007009510W WO 2007123961 A3 WO2007123961 A3 WO 2007123961A3
Authority
WO
WIPO (PCT)
Prior art keywords
vsv
cell culture
recovering
vesicular stomatitis
stomatitis virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/009510
Other languages
French (fr)
Other versions
WO2007123961A2 (en
Inventor
Yun Kang
Mark William Cutler
Amadou Affrey Ouattara
Kristen Elissa Syvertsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SI200730829T priority Critical patent/SI2007883T1/en
Priority to ES07755685T priority patent/ES2377356T3/en
Priority to AT07755685T priority patent/ATE539149T1/en
Priority to CN2007800140908A priority patent/CN101426905B/en
Priority to JP2009506566A priority patent/JP5129805B2/en
Priority to RU2008140137/10A priority patent/RU2484135C2/en
Priority to DK07755685.0T priority patent/DK2007883T3/en
Priority to EP07755685A priority patent/EP2007883B1/en
Priority to MX2008013494A priority patent/MX2008013494A/en
Priority to KR1020087028205A priority patent/KR101385927B1/en
Priority to PL07755685T priority patent/PL2007883T3/en
Priority to CA2648792A priority patent/CA2648792C/en
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to BRPI0710820-6A priority patent/BRPI0710820A2/en
Priority to AU2007240797A priority patent/AU2007240797B2/en
Publication of WO2007123961A2 publication Critical patent/WO2007123961A2/en
Publication of WO2007123961A3 publication Critical patent/WO2007123961A3/en
Priority to IL194629A priority patent/IL194629A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20251—Methods of production or purification of viral material
    • C12N2760/20252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Novel purification processes for obtaining vesicular stomatitis virus (VSV) of improved purity from mammalian cell culture are described herein. More particularly, in certain embodiments, a process is described for purifying VSV from cell culture fluid of a mammalian cell culture infected with VSV, the process comprising: clarifying the cell culture fluid by low-speed centrifugation and recovering the VSV in the supernatant; filtering the supernatant through a 0.2 to 0.45 µm filter and recovering the VSV in the filtered solution; loading the VSV filtered solution onto a anion exchange membrane adsorber equilibrated with a first pH buffered salt solution, eluting the VSV from the anion exchange membrane adsorber with a second pH buffered salt solution and recovering the eluted VSV fractions; purifying the recovered VSV by tangential flow filtration (TFF) using a TFF membrane having a molecular weight cutoff between 300 kDa and 1,000 kDa and recovering the VSV in the retentate, and filtering the VSV retentate through a 0.2 to 0.22 µm filter and recovering the VSV in the filtered solution.
PCT/US2007/009510 2006-04-20 2007-04-19 Purification processes for isolating purified vesicular stomatitis virus from cell culture Ceased WO2007123961A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
ES07755685T ES2377356T3 (en) 2006-04-20 2007-04-19 Purification procedure for the isolation of the purified vesicular stomatitis virus from a cell culture
AT07755685T ATE539149T1 (en) 2006-04-20 2007-04-19 PURIFICATION METHOD FOR ISOLATION OF PURIFIED VESICULAR STOMATITIS VIRUS FROM CELL CULTURE
CN2007800140908A CN101426905B (en) 2006-04-20 2007-04-19 Purification method of vesicular stomatitis virus isolated and purified from cell culture
JP2009506566A JP5129805B2 (en) 2006-04-20 2007-04-19 Purification process for isolation of purified vesicular stomatitis virus from cell culture
RU2008140137/10A RU2484135C2 (en) 2006-04-20 2007-04-19 Method of cleaning intended to produce cleaned virus of vesicular stomatitis from cellular culture
DK07755685.0T DK2007883T3 (en) 2006-04-20 2007-04-19 Purification Methods for Isolating Purified Vesicular Stomatitis Virus from Cell Culture
EP07755685A EP2007883B1 (en) 2006-04-20 2007-04-19 Purification processes for isolating purified vesicular stomatitis virus from cell culture
KR1020087028205A KR101385927B1 (en) 2006-04-20 2007-04-19 Purification processes for isolating purified vesicular stomatitis virus from cell culture
MX2008013494A MX2008013494A (en) 2006-04-20 2007-04-19 Purification processes for isolating purified vesicular stomatitis virus from cell culture.
SI200730829T SI2007883T1 (en) 2006-04-20 2007-04-19 Purification processes for isolating purified vesicular stomatitis virus from cell culture
CA2648792A CA2648792C (en) 2006-04-20 2007-04-19 Purification processes for isolating purified vesicular stomatitis virus from cell culture
PL07755685T PL2007883T3 (en) 2006-04-20 2007-04-19 Purification processes for isolating purified vesicular stomatitis virus from cell culture
BRPI0710820-6A BRPI0710820A2 (en) 2006-04-20 2007-04-19 process for purifying the vesicular stomatitis virus (vsv) from the cell culture fluid of a vsv infected mammalian cell culture; vsv purified according to the process; pharmaceutical composition; and immunogenic composition
AU2007240797A AU2007240797B2 (en) 2006-04-20 2007-04-19 Purification processes for isolating purified vesicular stomatitis virus from cell culture
IL194629A IL194629A (en) 2006-04-20 2008-10-07 Purification processes for isolating purified vesicular stomatitis virus from cell culture

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79337606P 2006-04-20 2006-04-20
US60/793,376 2006-04-20

Publications (2)

Publication Number Publication Date
WO2007123961A2 WO2007123961A2 (en) 2007-11-01
WO2007123961A3 true WO2007123961A3 (en) 2008-03-06

Family

ID=38625574

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/009510 Ceased WO2007123961A2 (en) 2006-04-20 2007-04-19 Purification processes for isolating purified vesicular stomatitis virus from cell culture

Country Status (19)

Country Link
US (1) US7875446B2 (en)
EP (1) EP2007883B1 (en)
JP (1) JP5129805B2 (en)
KR (1) KR101385927B1 (en)
CN (1) CN101426905B (en)
AT (1) ATE539149T1 (en)
AU (1) AU2007240797B2 (en)
BR (1) BRPI0710820A2 (en)
CA (1) CA2648792C (en)
CR (1) CR10380A (en)
DK (1) DK2007883T3 (en)
ES (1) ES2377356T3 (en)
IL (1) IL194629A (en)
MX (1) MX2008013494A (en)
PL (1) PL2007883T3 (en)
PT (1) PT2007883E (en)
RU (1) RU2484135C2 (en)
SI (1) SI2007883T1 (en)
WO (1) WO2007123961A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE547511T1 (en) 2004-12-23 2012-03-15 Medimmune Llc NON-TUMOR FORMING MDCK CELL LINE FOR REPRODUCTION OF VIRUSES
WO2008105931A2 (en) 2006-09-15 2008-09-04 Medimmune Vaccines, Inc. Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
PT2173861E (en) * 2007-06-15 2011-05-13 Amgen Inc METHODS OF TREATMENT OF CULTURAL CULTURE MEDIA FOR USE IN A BIORREACTOR
WO2009044414A1 (en) * 2007-10-02 2009-04-09 Gima S.P.A. Process and system for the industrial scale purification of bacteriophages intended for bacteriophage therapy
JP2011507523A (en) * 2007-12-21 2011-03-10 ワイス・エルエルシー Genetically modified attenuated vesicular stomatitis virus, composition and method of use
PL2307551T3 (en) * 2008-06-18 2017-07-31 Oxford Biomedica (Uk) Limited Purification of retroviral vectors
RU2547587C2 (en) * 2008-09-24 2015-04-10 Медиммун, Ллк Methods for cell culture, virus replication and purification
CN102215865B (en) * 2008-09-24 2013-10-30 米迪缪尼有限公司 Methods for purification of viruses
JP2012505863A (en) * 2008-10-17 2012-03-08 パシビア エルエルシー． Clarification method in high density cells
US20100143889A1 (en) * 2008-12-02 2010-06-10 Mayo Foundation For Medical Education And Research Rhabdoviridae virus preparations
CA2750055A1 (en) * 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Method for purifying viruses using a density gradient
ES2813398T3 (en) 2009-10-20 2021-03-23 Abbvie Inc Isolation and Purification of Anti-IL-13 Antibodies Using Protein A Affinity Chromatography
CN102191226A (en) * 2010-03-08 2011-09-21 北京清大天一科技有限公司 Separation and purification method for cell culture mixture
US8778653B2 (en) 2010-08-12 2014-07-15 Yisheng Biopharma Holdings Ltd. Method for reducing DNA impurities in viral compositions
AU2011336413B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
MX349294B (en) 2010-12-02 2017-07-21 Oncolytics Biotech Inc Lyophilized viral formulations.
CN103649297B (en) * 2011-07-08 2017-03-01 Emd密理博公司 Improvement depth filter for disposable biological technical method
US9610346B2 (en) 2012-03-23 2017-04-04 International Aids Vaccine Initiative Recombinant viral vectors
US9005888B2 (en) 2012-06-14 2015-04-14 System Biosciences, Llc Methods for microvesicle isolation and selective removal
CN104583386A (en) * 2012-08-20 2015-04-29 泰尔茂比司特公司 Concentrates components of the fluid circulated through the cell growth chamber
AU2013306080B2 (en) 2012-08-24 2019-01-31 Global Life Sciences Solutions Usa Llc Virus purification and formulation process
FR3010720B1 (en) 2013-09-16 2017-08-11 Genethon PROCESS FOR PRODUCING ENVELOPED VIRUSES
FR3014901B1 (en) 2013-12-17 2017-06-09 Genethon PROCESS FOR PURIFYING ENHANCED VIRUSES OR VIRTORS
CA3159833A1 (en) * 2014-05-21 2015-11-26 Unchained Labs Systems and methods for exchange of buffer solutions
CN106857498B (en) * 2016-12-27 2021-05-14 科兴（大连）疫苗技术有限公司 Cell cryopreservation protective solution without dimethyl sulfoxide and application thereof
CN107964037A (en) * 2017-05-16 2018-04-27 浙江海隆生物科技有限公司 CHO cell expression system-based purification method and application of recombinant classical swine fever E2 protein
CN110317832B (en) * 2018-03-28 2022-07-05 西比曼生物科技（香港）有限公司 GMP (good manufacturing practice) scale preparation method of purified preparation of recombinant lentiviral vector
CN110317791A (en) 2018-03-29 2019-10-11 西比曼生物科技（香港）有限公司 The method of GMP grades of serum free suspension cell large-scale production slow virus
EP3823677A4 (en) * 2018-07-19 2022-06-01 Helixmith Co., Ltd. FREEZE-DRIED PHARMACEUTICAL COMPOSITIONS INTENDED FOR NAKED-DNA GENE THERAPY
AU2019310459A1 (en) * 2018-07-24 2021-02-18 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
TWI894135B (en) 2019-01-25 2025-08-21 德商百靈佳殷格翰國際股份有限公司 Recombinant rhabdovirus encoding for ccl21
US20220243224A1 (en) * 2019-04-15 2022-08-04 Children's Hospital Medical Center Viral vector manufacturing methods
CN110305850A (en) * 2019-05-15 2019-10-08 苏州奥特铭医药科技有限公司 A method of oncolytic virus is prepared using 293 cell productions
PH12023550070A1 (en) 2020-07-10 2024-03-11 Boehringer Ingelheim Int Process for producing a purified rhabdovirus from cell culture
WO2025052417A1 (en) * 2023-09-05 2025-03-13 Auro Vaccines Private Limited Thermostable composition comprising vesiculo virus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168943B1 (en) * 1995-05-04 2001-01-02 Yale University Methods for making modified recombinant vesiculoviruses
WO2003093463A1 (en) * 2002-04-30 2003-11-13 Oncolytics Biotech Inc. Improved viral purification methods
WO2005098009A2 (en) * 2004-04-09 2005-10-20 Wyeth Synergistic attenutation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556556A (en) * 1984-03-23 1985-12-03 Advanced Genetics Research Institute Vaccine for the prevention of vesicular stomatitis virus infection
PT702085E (en) 1994-07-18 2004-04-30 Karl Klaus Conzelmann NON-SEGMENTED CHEMICAL RNA VIRUS INFECTIOUS RECOMBINANT
FR2737730B1 (en) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc PROCESS FOR PURIFYING VIRUSES BY CHROMATOGRAPHY
US6261823B1 (en) * 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
IL135507A0 (en) * 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
KR100912362B1 (en) * 1998-02-17 2009-08-19 쉐링 코포레이션 Methods for purifying virus preparations
WO2003031583A2 (en) * 2001-10-09 2003-04-17 University Of Miami Generation of virus-like particles by vsv
US20030175688A1 (en) 2002-03-15 2003-09-18 Rukmini Pennathur-Das Method for the purification and production of oncolytic adenoviruses
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
DE60335672D1 (en) * 2002-05-14 2011-02-17 Merck Sharp & Dohme PROCESS FOR CLEANING ADENOVIRUS
US20050009168A1 (en) 2003-05-12 2005-01-13 Robbins Joan Marie Methods and apparatus for Adeno associated virus purification
DE102004004043B4 (en) 2004-01-27 2013-04-18 Apanovis Biotechnologie Gmbh Purification of high molecular weight compounds by affinity membrane chromatography
NZ548495A (en) * 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
WO2006011580A1 (en) 2004-07-27 2006-02-02 Genomidea, Inc. Method of purifying virus envelope

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168943B1 (en) * 1995-05-04 2001-01-02 Yale University Methods for making modified recombinant vesiculoviruses
WO2003093463A1 (en) * 2002-04-30 2003-11-13 Oncolytics Biotech Inc. Improved viral purification methods
WO2005098009A2 (en) * 2004-04-09 2005-10-20 Wyeth Synergistic attenutation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BURKHART CHRISTOPH ET AL: "Characterization of T-helper epitopes of the glycoprotein of vesicular stomatitis virus", JOURNAL OF VIROLOGY, vol. 68, no. 3, 1994, pages 1573 - 1580, XP002462510, ISSN: 0022-538X *
DE LAS MERCEDES SEGURA ET AL: "Downstream processing of oncoretroviral and lentiviral gene therapy vectors", BIOTECHNOLOGY ADVANCES, ELSEVIER PUBLISHING, BARKING, GB, vol. 24, no. 3, 30 January 2006 (2006-01-30), pages 321 - 337, XP005362294, ISSN: 0734-9750 *
HECHT T T ET AL: "LIMITATION OF VESICULAR STOMATITIS VIRUS INFECTION BY THE HOST RESPONSE TO VESICULAR STOMATITIS VIRUS ASSOCIATED CELLULAR ANTIGENS", JOURNAL OF IMMUNOLOGY, vol. 129, no. 4, 1982, pages 1736 - 1741, XP002462511, ISSN: 0022-1767 *
MORENWEISER R: "Downstream processing of viral vectors and vaccines", GENE THERAPY, vol. 12, no. Suppl. 1, October 2005 (2005-10-01), pages S103 - S110, XP002462513, ISSN: 0969-7128 *
SCHERR M ET AL: "Efficient gene transfer into the CNS by lentiviral vectors purified by anion exchange chromatography.", GENE THERAPY, vol. 9, no. 24, December 2002 (2002-12-01), pages 1708 - 1714, XP002462512, ISSN: 0969-7128 *
YAMADA KAORU ET AL: "LENTIVIRUS VECTOR PURIFICATION USING ANION EXCHANGE HPLC LEADS TO IMPROVED GENE TRANSFER", BIOTECHNIQUES, INFORMA LIFE SCIENCES PUBLISHING, WESTBOROUGH, MA, US, vol. 34, no. 5, May 2003 (2003-05-01), pages 1074 - 1080, XP001537620, ISSN: 0736-6205 *

Also Published As

Publication number Publication date
IL194629A (en) 2013-11-28
JP2009534030A (en) 2009-09-24
DK2007883T3 (en) 2012-02-06
BRPI0710820A2 (en) 2011-08-23
US20070249019A1 (en) 2007-10-25
AU2007240797B2 (en) 2013-05-23
RU2484135C2 (en) 2013-06-10
WO2007123961A2 (en) 2007-11-01
KR20080111544A (en) 2008-12-23
US7875446B2 (en) 2011-01-25
PL2007883T3 (en) 2012-07-31
CR10380A (en) 2008-12-02
KR101385927B1 (en) 2014-04-24
EP2007883A2 (en) 2008-12-31
CA2648792A1 (en) 2007-11-01
CA2648792C (en) 2016-06-21
RU2008140137A (en) 2010-05-27
IL194629A0 (en) 2011-08-01
SI2007883T1 (en) 2012-02-29
ATE539149T1 (en) 2012-01-15
AU2007240797A1 (en) 2007-11-01
MX2008013494A (en) 2009-01-26
ES2377356T3 (en) 2012-03-26
JP5129805B2 (en) 2013-01-30
PT2007883E (en) 2012-02-17
CN101426905B (en) 2013-03-27
CN101426905A (en) 2009-05-06
EP2007883B1 (en) 2011-12-28

Similar Documents

Publication Publication Date Title
WO2007123961A3 (en) Purification processes for isolating purified vesicular stomatitis virus from cell culture
JP3746223B2 (en) Method for removing protein aggregates and viruses from a protein solution
KR101868858B1 (en) Method for Purifying Human Serum Albumin from Transgenic Rice Grain
CN103014114B (en) Method for preparing 7-aminocephalosporanic acid via enzymic method
WO2006039588A3 (en) Devices and methods for integrated continuous manufacturing of biological molecules
EP1457460A3 (en) Water purification system and method, and module for the system
CN102040531B (en) Method for extracting L-isoleucine
JP2008512473A5 (en)
KR101376410B1 (en) Method of concentrating shear-sensitive biopolymers using hollow fibre membranes
CN103012470A (en) Method for preparing liquid phytic acid from rapeseed dregs
US20160340377A1 (en) Method for purifying oxidized form of beta-nicotinamide adenine dinucleotide
MY126838A (en) Purification of protein inclusion bodies by crossflow microfiltration.
CN110698472B (en) A kind of purification method of pyrroloquinoline quinone
CN104278071A (en) Extraction method of cephalosporin C
CN102229540A (en) Method for producing lysine acetate for injection
WO2003057720A3 (en) Recovery of biofilament proteins from biological fluids
ATE408010T1 (en) PURIFICATION OF PLASMID DNA BY FILTRATION
CN1101396C (en) Isolation of clavulanic acid from fermentation broth by ultrafiltration
JP3218193B2 (en) Method for ultrafiltration of biological substrates containing peptides or proteins
Higuchi et al. Rejection of single stranded and double stranded DNA by porous hollow fiber membranes
CN106146609B (en) A kind of method of utilization membrane separation technique separating-purifying glutathione from glutathione cuprous salt
CN212881404U (en) A nucleotide solution purification and concentration system based on roll-type ultrafiltration and nanofiltration technology
CN214829439U (en) The structure of a composite filter element
CN2751017Y (en) Composite water purifying filter element
CN204824431U (en) Membrane filtration purification device

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07755685

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 194629

Country of ref document: IL

Ref document number: 2007240797

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2648792

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 571867

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 8587/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009506566

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200780014090.8

Country of ref document: CN

Ref document number: 08111777

Country of ref document: CO

Ref document number: 2007755685

Country of ref document: EP

Ref document number: CR2008-010380

Country of ref document: CR

Ref document number: MX/A/2008/013494

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007240797

Country of ref document: AU

Date of ref document: 20070419

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087028205

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008140137

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0710820

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081020